Back to results
US 2020/0270211 A1Published application
Compounds, compositions and methods of use
AssigneeAquinnah Pharmaceuticals, Inc.
InventorsDuane A. Burnett, Joseph P. Vacca
Life of this patent
Estimating the term…
Abstract
Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
Claims55
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- each of Ring A and Ring B is independently cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- X is C(R′)(R″), O, or S(O)x;
- each of L1 and L2 is independently —C1-C6 heteroalkyl-, —NRA—, —C(O)NRA—, —NRAC(O)—, —C(O)NRA—C1-C6 alkyl-, —C1-C6 alkyl-C(O)NRA—, —NRAC(O)—C1-C6 alkyl-, —C1-C6 alkyl-NRAC(O)—, —C(O)NRA—C1-C6 heteroalkyl-, —C1-C6 heteroalkyl-C(O)NRA—, —NRAC(O)—C1-C6 heteroalkyl-, —C1-C6 heteroalkyl-NRAC(O)—, —C1-C6 heteroalkyl-C(O)—, or —C(O)—C1-C6 heteroalkyl-, each of which is optionally substituted with 1-5 R4;
- each of R1 and R3 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, halo, cyano, nitro, azido, cycloalkyl, heterocyclyl, aryl, heteroaryl, —ORB, —C(O)RD, —C(O)ORB, —NRARC, —NRAC(O)RD, —S(O)xRE, —OS(O)xRE, —C(O)NRAS(O)xRE, —NRAS(O)xRE, or —S(O)xNRA, each of which is optionally substituted with 1-5 R5;
- or
- each R2 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, halo, cyano, or nitro;
- each of R′ and R″ is independently H, C1-C6 alkyl, or C1-C6 heteroalkyl;
- each R4 is independently deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, —ORB, —C(O)RD, —C(O)ORB, —C(O)NRARC, or —SRE, each of which is optionally substituted with 1-5 R6;
- or one R4, taken together with the atoms to which it is attached, forms a ring (e.g., a 5-7 membered ring) with Ring A, optionally substituted with 1-5 R5;
- or two R4, taken together with the atoms to which they are attached, form a ring (e.g., a 3-7 membered ring), optionally substituted with 1-5 R6;
- each R5 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, halo, cyano, or oxo;
- or two R5, taken together with the atoms to which they are attached, form a ring (e.g., a 3-7 membered ring), optionally substituted with 1-5 R6;
- each RA, RB, RC, RD, or RE is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-4 R6;
- or RA and RC, together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R8;
- each R6 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C2-C6 heteroalkenyl, C2-C6 heteroalkynyl, C1-C6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, or nitro;
- each of n, o, and p is independently 0, 1, 2, 3, 4, 5, or 6;
- and
- x is 0, 1, or 2;
16 more elements
(canceled)
7-9. (canceled)
(canceled)
(canceled)
20-21. (canceled)
(canceled)
26-27. (canceled)
(canceled)
33-36. (canceled)
(canceled)
40-42. (canceled)
45-46. (canceled)
(canceled)
51-54. (canceled)
(canceled)
65-66. (canceled)
69-73. (canceled)
Dependencies are inferred from the claim text.